Morphelan

Morphelan®

Pain management A proprietary formulation of morphine. See Morphine.
References in periodicals archive ?
Avinza, the new brand name for Morphelan, is a morphine sulphate extended release capsule for the once-a-day treatment of chronic and moderate to severe pain in patients who require continuous therapy over a lengthy period.
Ligand Selects Avinza as Brand Name for Oral, Once-Daily Sustained-Release Opioid Formerly Called Morphelan Subject to final FDA approval of the NDA, Ligand expects to commercialize its once-daily sustained release opioid product under the brand name Avinza.
believe we have with Morphelan," said Thomas Silberg, Senior
New Drug Application (NDA) for Morphelan, and Elan has
5 million incurred by Targon Corporation, CYTOGEN's subsidiary, to obtain exclusive worldwide rights of Morphelan from Elan Corporation, plc.
0 million milestone payment to The Dow Chemical Company, the licensing fee relating to Morphelan, and the impact of development and marketing efforts on the Company's new products.
Food and Drug Administration (FDA) issued to Elan Corporation, plc, an approvable letter regarding the New Drug Application (NDA) for Morphelan Rapid Onset Extended Release (ROER(TM)), a once-daily, modified release, oral dosage form of morphine licensed exclusively to Ligand in the United States and Canada for the management of moderate to severe chronic pain.
Ligand has certain marketing rights to Morphelan in the U.
Note: Morphelan is a trademark of Elan Corporation, plc.
In November 1998, Elan licensed exclusively to Ligand in the United States and Canada its proprietary product Morphelan for the management of pain in oncology and HIV patients, for which rights Ligand agreed to pay Elan certain up-front license fees and milestones upon the occurrence of certain events.